An experimental Alzheimer’s drug called crenezumab did not prevent or slow mental decline in patients with a genetic mutation that greatly raises the risk of developing the disease, the results of a decade-long clinical trial show.
An experimental Alzheimer’s drug called crenezumab did not prevent or slow mental decline in patients with a genetic mutation that greatly raises the risk of developing the disease, the results of a decade-long clinical trial show.